Related Experiment Video
Updated: May 2, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Mildly oxidized LDL induces activation of platelet-derived growth factor beta-receptor pathway
I Escargueil-Blanc1, R Salvayre, N Vacaresse
1INSERM U-466 and the Biochemistry Department, IFR-31, CHU Rangueil, Toulouse, France.
Background:
Mildly oxidized LDL (moxLDL) is thought to play a role in atherogenesis. MoxLDL induces derivatization of cell proteins and triggers a variety of intracellular signaling. We aimed to investigate whether moxLDL-induced protein derivatization may influence the activity of platelet-derived growth factor receptor beta (PDGFRbeta), a tyrosine kinase receptor of major importance in vascular biology and atherogenesis.
Methods And Results:
In cultured rabbit arterial smooth muscle cells, moxLDL induces activation of the PDGFRbeta signaling pathway, as shown by PDGFRbeta tyrosine phosphorylation on Western blot and coimmunoprecipitation of SH2-containing proteins. The cellular events involved in the moxLDL-induced PDGFRbeta activation can be summarized as follows. Oxidized lipids from moxLDL trigger two phases of PDGFRbeta activation involving two separate mechanisms, as shown by experiments on cultured cells (in situ) and on immunopurified PDGFRbeta (in vitro): (1) the first phase may be mediated by 4-hydroxynonenal, which induces PDGFRbeta adduct formation and subsequent PDGFRbeta activation (antioxidant-insensitive step); (2) the second phase involves ceramide-mediated generation of H(2)O(2) (these steps being inhibited by tosylphenylalanylchloromethylketone, an inhibitor of ceramide formation, and by antioxidant BHT, exogenous catalase, or overexpressed human catalase). Because 4-hydroxynonenal-PDGFRbeta adducts are also detected in atherosclerotic aortas, it is suggested that this novel mechanism of moxLDL-induced PDGFRbeta activation may occur during atherogenesis.
Conclusions:
MoxLDL acts as a local autoparacrine mediator in the vascular wall, and PDGFRbeta acts as a sensor for both oxidized lipids and oxidative stress. This constitutes a novel mechanism of PDGFRbeta activation in atherosclerotic areas.
Insights
Mildly oxidized LDL (moxLDL) activates platelet-derived growth factor receptor beta (PDGFRbeta) through two distinct mechanisms, involving 4-hydroxynonenal and ceramide. This novel pathway may contribute to atherogenesis.
Area of Science:
- Vascular Biology
- Atherosclerosis Research
- Cell Signaling
Background:
- Mildly oxidized low-density lipoprotein (moxLDL) is implicated in atherogenesis.
- moxLDL induces protein modification and intracellular signaling cascades.
- The role of moxLDL in activating platelet-derived growth factor receptor beta (PDGFRbeta) was investigated.
Purpose of the Study:
- To determine if moxLDL-induced protein modification influences PDGFRbeta activity.
- To elucidate the mechanisms of PDGFRbeta activation by moxLDL.
Main Methods:
- Experiments were conducted on cultured rabbit arterial smooth muscle cells.
- PDGFRbeta tyrosine phosphorylation and SH2-containing protein coimmunoprecipitation were assessed.
- In situ and in vitro experiments were performed on immunopurified PDGFRbeta.
Main Results:
- moxLDL activates the PDGFRbeta signaling pathway, evidenced by tyrosine phosphorylation.
- Two phases of PDGFRbeta activation by moxLDL were identified.
- Phase 1 involves 4-hydroxynonenal-induced PDGFRbeta adduct formation (antioxidant-insensitive).
- Phase 2 involves ceramide-mediated hydrogen peroxide generation (inhibited by ceramide inhibitors and antioxidants).
- 4-hydroxynonenal-PDGFRbeta adducts were detected in atherosclerotic aortas.
Conclusions:
- moxLDL functions as an autoparacrine mediator in the vascular wall.
- PDGFRbeta serves as a sensor for oxidized lipids and oxidative stress.
- A novel mechanism for PDGFRbeta activation in atherosclerotic areas was proposed.
More Related Videos
Related Concept Videos
Receptor-mediated Endocytosis
Inflammation
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cholesterol: Significance and Regulation
Considering cholesterol and...
Coronary Artery Disease II: Pathophysiology
Atherosclerosis I: Introduction

